Finzati - Logo
VRTX logo

Vertex Pharmaceuticals Incorporated

VRTX • Biotechnology
$546.12
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$139.64B
Growth
18.7%
Cash Flow
4/5
Trend
Mostly stable
Evidence
Stable or improving margins · 32.7%Positive revenue growth · 12.6%Positive free cash flow · 12.49Consistent free cash flow · 4/5Manageable debt level · 0.21
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 12:09 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$546.12
Change0.00%
Shares Out255.70M
Market Cap$139.64B
Enterprise Value$131.79B
52W Range362.50 - 533.67
Beta0.29
P/E31.70
P/S11.06
P/B6.90
P/FCF36.79
EV/Sales10.44

Investment DNA

How strong this company looks for long-term investors

80
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
87/100
Price Attractiveness
Cheap or expensive today
38/100
Why this score▼
Stable or improving margins · 32.7%Positive revenue growth · 12.6%Positive free cash flow · 12.49Consistent free cash flow · 4/5Manageable debt level · 0.21Healthy liquidity · 2.9

Analyst view

Analyst sentiment and price target

VRTX
Analyst sentiment
Based on 56 analyst votes · 2026-09-05
92/100
Bullish
Bullish
48
Hold
7
Bearish
1
Price Target
2026-08-06
Low
$350.00
Mean
$552.93
Median
$576.00
High
$617.00

Company Overview

IPO: 7/24/1991
Industry: Biotechnology
P/B i: 6.90
Debt / Equity i: 0.21
Operating Margin: 39.43%
Net Margin: 32.74%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.21
Current Ratio: 2.90
Quick Ratio: 2.46
Status: Strong

Insider Transactions

Recent executive and insider activity

Sachdev Amit
Transaction: 07/21/2026
BUY
Change
+8,251
Price
Not reported
Filing
07/23/2026
Type
BUY
Tatsis Ourania
Transaction: 07/21/2026
BUY
Change
+8,251
Price
Not reported
Filing
07/23/2026
Type
BUY
Garber Alan M
Transaction: 07/15/2026
BUY
Change
—
Price
Not reported
Filing
07/17/2026
Type
BUY